These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI. Ferguson JJ; Wilson JM; Diez J Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162 [TBL] [Abstract][Full Text] [Related]
10. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697 [TBL] [Abstract][Full Text] [Related]
11. IIb/IIIa Receptor Blockers. Preface. van den Brand M; O'Neill W Semin Interv Cardiol; 1999 Jun; 4(2):59-60. PubMed ID: 10473873 [No Abstract] [Full Text] [Related]
12. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. Koster A; Meyer O; Fischer T; Kukucka M; Krabatsch T; Bauer M; Kuppe H; Hetzer R J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1254-5. PubMed ID: 11726910 [No Abstract] [Full Text] [Related]
13. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Fernandez JS; Sadaniantz A Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658 [No Abstract] [Full Text] [Related]
14. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423 [TBL] [Abstract][Full Text] [Related]
15. Tirofiban in unstable coronary disease. Liron M N Engl J Med; 1998 Oct; 339(16):1163-5. PubMed ID: 9776651 [No Abstract] [Full Text] [Related]
16. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. Cox D; Smith R; Quinn M; Theroux P; Crean P; Fitzgerald DJ J Am Coll Cardiol; 2000 Nov; 36(5):1514-9. PubMed ID: 11079651 [TBL] [Abstract][Full Text] [Related]
17. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation. Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357 [TBL] [Abstract][Full Text] [Related]
18. A laboratory method for parallel determination of platelet aggregation and thrombin generation. Köstenberger M; Gallistl S; Cvirn G; Muntean W Clin Lab; 2004; 50(1-2):41-8. PubMed ID: 15000219 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of low-molecular-weight heparin in acute coronary syndromes. Wallentin L Am Heart J; 2000 Feb; 139(2 Pt 2):S29-32. PubMed ID: 10650313 [No Abstract] [Full Text] [Related]
20. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]